人免疫缺陷病毒感染者对严重急性呼吸综合征冠状病毒 2 mRNA 疫苗的抗体反应的决定因素。
Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV.
机构信息
Basel Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, University Hospital Basel, University of Basel, Basel.
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich.
出版信息
AIDS. 2022 Aug 1;36(10):1465-1468. doi: 10.1097/QAD.0000000000003246. Epub 2022 Jul 9.
We identified determinants of SARS-CoV-2 mRNA vaccine antibody response in people with HIV (PWH). Antibody response was higher among PWH less than 60 years, with CD4+ cell count superior to 350 cells/μl and vaccinated with mRNA-1273 by Moderna compared with BNT162b2 by Pfizer-BioNTech. Preinfection with SARS-CoV-2 boosted the antibody response and smokers had an overall lower antibody response. Elderly PWH and those with low CD4+ cell count should be prioritized for booster vaccinations.
我们确定了 HIV 感染者（PWH）中 SARS-CoV-2 mRNA 疫苗抗体反应的决定因素。与辉瑞-生物技术公司的 BNT162b2 相比，年龄小于 60 岁、CD4+细胞计数超过 350 个/μl 且接种 Moderna 的 mRNA-1273 的 PWH 的抗体反应更高。SARS-CoV-2 感染前增强了抗体反应，吸烟者的总体抗体反应较低。老年 PWH 和 CD4+细胞计数低的患者应优先考虑加强免疫接种。
Zotero 插件